Bayer's Pipeline Gains Speed While a Missouri Courtroom Holds the Reins

Bayer won FDA nods for sevabertinib and a wider Kerendia label, but its valuation still hinges on the pending Missouri Roundup settlement ruling.

Two fresh regulatory green lights in the space of a week have given Bayer's oncology and kidney franchises a visible boost — yet the German group's valuation still hinges on a ruling that has nothing to do with its laboratories.

On September 9, the US Food and Drug Administration granted accelerated approval to sevabertinib, a targeted agent cleared as a first-line option for adults with HER2-mutated non-small cell lung cancer. The same day, Bayer struck a commercial agreement with Neste to jointly scale up newgold winter rapeseed for biofuel production, extending its agricultural reach beyond conventional crop protection and seed markets.

Those announcements landed just days after the FDA widened the label for Kerendia, Bayer's kidney drug, to cover chronic kidney disease linked to type-1 diabetes following an expedited review. Management describes the compound as the first new treatment option for that specific condition in the United States in three decades, and expects it to generate peak annual sales north of EUR 3 billion.

Second-quarter figures shift the spotlight inward

The pipeline news arrives alongside a set of quarterly numbers that have nudged investors' attention toward the underlying business. Revenue for the second quarter of 2026 came in at EUR 10.87 billion, a rise of 2.2% once currency and portfolio effects are stripped out. Adjusted EBITDA reached EUR 2.14 billion, while net income swung to a profit of EUR 219 million from a loss of EUR 199 million a year earlier. Adjusted earnings per share stood at EUR 0.95.

For the full year, the company reiterated its guidance: adjusted EBITDA of between EUR 9.6 billion and EUR 10.1 billion, and core earnings per share in a range of EUR 4.30 to EUR 4.90. That corridor has become the yardstick by which the market will judge whether Bayer's earnings power is strong enough to keep whittling down its obligations at the pace it has mapped out. Free cash flow after servicing ongoing commitments is the figure that ultimately matters for valuation.

Debt relief, with strings attached

More than a month ago, a partnership with funds managed by Apollo delivered a measure of balance-sheet breathing room. As a result, Bayer trimmed its forecast for net financial debt to between EUR 29 billion and EUR 30 billion for the year. Since that arrangement was announced, the share price has slipped 1.7%.

Should momentum in either the agricultural division or the pharmaceuticals unit falter, that deleveraging plan would come under immediate strain. Conversely, if the group can land at the upper end of its operating target, it gains leeway to fund research efforts such as May's acquisition of Perfuse Therapeutics, a move aimed at bolstering its ophthalmology portfolio.

The legal overhang that refuses to clear

Against these operational bright spots, the US litigation landscape remains the single most influential factor shaping how the stock is priced. A little over a week ago, the Missouri Circuit Court heard arguments on whether to approve the sweeping Roundup settlement. Judge Boyer is weighing the agreement, which would see Bayer pay out declining sums totaling as much as USD 7.25 billion over up to 21 years. A ruling on final approval is still pending, and press reports suggest the decision could take several more weeks.

A June 26 Supreme Court ruling in the Durnell case had already tilted the legal terrain in Bayer's favor by establishing that the federal FIFRA statute preempts state-level warning requirements — a finding that undercut a central pillar of many plaintiffs' claims. Even so, if the Missouri court demands substantial revisions or rejects the settlement outright, the company could face unpredictable cash outflows and protracted follow-on litigation.

What could still go wrong

Beyond the courtroom, operational hazards persist in Bayer's core markets. Unfavorable weather, pricing pressure in crop protection, or softening seed demand could push adjusted EBITDA toward the lower bound of guidance, narrowing the company's financial room to maneuver almost instantly. Faith in the durability of the annual targets would erode quickly in that scenario.

On the other side of the ledger, a sustained stabilization of the core business would amplify the benefit of any legal progress, giving market participants reason to apply smaller risk discounts to the remaining litigation exposure.

Since the start of the year, the stock has climbed 30%, reflecting cautious optimism about the turnaround. After a 2.3% pullback on Friday, the shares closed at EUR 47.96. Whether Bayer's new therapies live up to their projected peak sales — and whether the Missouri judge signs off on the multibillion-dollar accord — will determine what happens next. Until that ruling lands, the operating trend remains the benchmark against which the re-rating stands or falls.